Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Epilepsy
•
General Internal Medicine
•
Neurology
When do you consider switching a generic formulation antiseizure medication to the brand formulation?
Related Questions
How do you approach escalating anti-seizure medication treatment of patients with atypical seizure semiologies?
How do you advise patients with epilepsy that are planning pregnancy and use invasive neuromodulation for treatment of their epilepsy?
What is your clinical threshold for treating a potential monoclonal gammopathy of thrombotic significance?
What strategies do you find helpful in advanced care planning with patients/families who are very "miracle" centered?
How do you approach tapering high dose continuous infusions for status epilepticus in patients experiencing serious medication-related toxicity?
Do you prescribe GLP-1 agonists to diabetic patients admitted with minor CVA or TIA for secondary stroke prevention, as suggested by the LAMP trial?
How do you decide whether to place an NGT or PEG tube in patients with dysphagia precluding adequate PO nutritional intake?
How do you approach a patient who develops a rest tremor after chemotherapy?
When do you consider cannabidiol for treatment of epilepsy?
Do you titrate anti-seizure medication doses in the setting of high or low serum drug levels if patients remain seizure free?
